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Severe immune dysregulation with neurological
impairment and minor bone changes in a child
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Abstract
Spondyloenchondrodysplasia (SPENCD) is a rare skeletal dysplasia, characterized by metaphyseal lesions, neurological
impairment and immune dysregulation associated with lupus-like features. SPENCD is caused by biallelic mutations in
the ACP5 gene encoding tartrate-resistant phosphatase. We report on a child, who presented with spasticity,
multisystem inflammation, autoimmunity and immunodeficiency with minimal metaphyseal changes due to
compound heterozygosity for two novel ACP5 mutations. These findings extend the phenotypic spectrum of
SPENCD and indicate that ACP5 mutations can cause severe immune dysregulation and neurological impairment even
in the absence of metaphyseal dysplasia.
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Background
Spondyloenchondrodysplasia (SPENCD) is a rare skeletal
dysplasia, characterized by enchondromatous non-ossifying
metaphyseal and spondylar lesions [1, 2]. Patient may
exhibit varying degrees of neurological impairment
including spasticity, developmental delay and basal gan-
glia calcification [3]. In addition, signs of autoimmune
disease resembling systemic lupus erythematosus (SLE)
are commonly observed [2]. Furthermore, patients may
also suffer from recurrent infections. SPENCD is inhe-
rited in an autosomal recessive manner and was re-
cently shown to be caused by bilallelic mutations in the
ACP5 gene encoding tartrate-resistant phosphatase
(TRAP) [4, 5]. It was shown that loss of TRAP activity
in patients with SPENCD results in decreased dephos-
phorylation of osteopontin, a cytokine present in bone-
dissolving osteoclasts as well as in antigen-presenting
macrophages and dendritic cells [4, 5]. Elevated levels of
active phosphorylated osteopontin are thought to be re-
sponsible for increased bone resorption and immune
dysregulation resulting in skeletal abnormalities and an
altered cytokine profile characterized by overproduction
of type I interferon.
Case presentation
We report on a 9 year-old Caucasian girl who was born
at term to non-consanguineous healthy parents after an
uncomplicated pregnancy. Following a period of normal
development, an increased muscle tone of the lower
limbs was first noted at 6 months of age. An MRI of the
brain was normal at this time. Laboratory testing did not
reveal any signs of inflammation, lysosomal storage
diseases or neurometabolic disease. At 18 months of age
she was unable to sit unsupported or to crawl. Hearing
and vision were not impaired. Liver function tests were
abnormal (ALAT 107 U/l, ASAT 133 U/l) and she tested
positive for IgG against EBNA1, VCA-p18, VCA-p23,
IEA-BZLF1, EA-p138 and EA-p54 consistent with a past
EBV infection. Infections with cytomegalovirus, hepatitis
B and C viruses were excluded. Examination of cerebro-
spinal fluid (CSF) revealed normal values for cell counts,
protein, glucose, lactate and neurotransmitters. However,
interferon-α was elevated in CSF (6 IU/ml [<2 IU/ml])
as well as in serum (100 IU/ml [<2 IU/ml]) which was
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attributed to chronic EBV infection. At 2.5 years of age,
thrombocytopenia (4/nl) and mild anaemia (haemoglobin
8.8 g/dl) were noted. The patient now tested positive for
autoantibodies including ANA (1:1280; speckled pattern),
antibodies against Ro/SS-A, La/SS-B, topoisomerase as
well as p-ANCA (1:160). Complement levels were
reduced (C3 39 mg/dl [80–150 mg/dl]; C4 7.8 mg/dl
[12.5–42.5 mg/dl]). An MRI of the brain showed
delayed myelinisation, no calcifications were seen on
a CT scan. Single-photon emission computed tomog-
raphy revealed areas of disturbed perfusion in the
frontal, temporal and parietal regions of the cortex as
well as in the basal ganglia consistent with cerebral
vascular disease (Fig. 1a). The patient was started on
methylprednisolone pulse therapy every 8 weeks. The
parents noted some improvement of spasticity. At 4.5 years
of age, elevated transaminases as well as ANA (1:640) and
p-ANCA antibodies (1:160) were still detectable. Myco-
phenolate mofetil (250 mg/day) was started with some
improvement of motor function. Two months later, the
patient presented with a mucosal bleeding disorder
that was attributed to thrombocytopenia (33/nl). The girl
was started on prednisolone (5 mg every other day).
Mycophenolate was stopped for 6 weeks, during
which time platelets further decreased suggesting that
thrombocytopenia was not a side effect of this medi-
cation. Mycophenolate was therefore restarted with
400 mg daily. Under this combination therapy her
platelet count rose to 248/nl.
At 5 years of age the child was hospitalized with high
fever, pneumonia and bloody diarrhoea. She tested posi-
tive for mycoplasma IgG, but no IgM, and was started on
erythromycin. No infectious agents were detected in the
stool. Anaemia worsened (Hb 6.0 g/dl) and the girl re-
quired a blood transfusion. A positive direct Coombs test
confirmed autoimmune haemolytic anaemia. The patient
also developed erythema nodosum of the lower limbs and
a severe polyarthritis affecting wrist, hip, ankle and knee
joints. During the course of this illness, antibodies against
β2-glycoprotein IgM and IgG as well as anti-cardiolipin
IgG and IgM along with a severely altered coagulation
profile due to anti-phospholipid syndrome were noted.
Prednisolone was increased to 20 mg daily, which led to a
marked improvement of clinical symptoms.
In the following months, the patients experienced
recurrent infections affecting the urinary tract and upper
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Fig. 1 Clinical findings. a Single-photon emission computed tomography (SPECT) of the brain at 5 years of age demonstrating speckled areas of
reduced perfusion predominantly in the frontal, temporal and parietal regions of the right cortex as well as in parts of the basal ganglia consistent
with cerebral vascular lesions. Radiographs of the left hand and knee taken at 4 (b, c) and 9 years of age (d, e), respectively, showing discrete metaphyseal
irregularities. In addition, reduced mineralization of the lower extremities caused by impaired physical activity is seen at 9 years of age
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airways as well as an episode of severe aphthous stoma-
titis accompanied by Quinke oedema of the face. In
addition, the girl developed recurrent petechiae of the
face, erythema nodosum of the feet as well as mild
sugillations of the oral mucosa despite normal platelet
counts. Prednisolone could not be reduced below 10 mg
per day because of recurring polyarthritis. Further im-
munological work up revealed a reduced number of CD4+
cells (268/μl [700–2200/μl]), B cells (0.2 % [1–4 %]) and
natural killer cells (2 % [4–26 %]).
At 5.5 years of age, she presented with a high fever,
generalized vasculitis, encephalopathy with seizures and
respiratory insufficiency due to interstitial pneumonia
requiring 2 days of mechanical ventilation. She also
developed polyarthritis and nephritis with proteinuria.
Blood cultures were positive for ESBL-positive Klebsiella
pneumoniae. Finally, the diagnosis of acute measles infec-
tion was made, in addition to reactivated EBV infection.
The girl had not been vaccinated with life vaccines in
the past due to immunosuppression and in part due
to parental refusal. Seizures were treated with phenobar-
bital and levetiracetam. Antibiotic therapy with cefuroxime
and imipenem were started along with methylprednisolone
pulse therapy for 3 days. She also received immunoglobu-
lins because of severe hypogammaglobulinaemia.
At 7 years of age, the girl presented with high fever,
severe polyarthritis, enthesitis of the wrists and oral
mucositis with sugillations. At that time, mumps, herpes
simplex stomatitis and adenoviral infection were diag-
nosed, in addition to EBV reactivation. The patient
received intravenous IgG substitution, acyclovir and
prednisolone 15 mg per day. In addition, antibiotic
therapy using amoxicillin/sulbactam was started and
continued at a prophylactic dosage for half a year because
of recurrent genital ulcers and abscesses.
As part of her diagnostic work-up, genetic testing
for TNF-associated periodic syndrome, Hyper IgD syn-
drome, familial Mediterranean fever, cryopyrin associated
periodic syndrome and Aicardi-Goutières syndrome was
performed with negative results. Whole body MRI at that
time did not reveal structural changes of the joints inclu-
ding wrists, knees and spine. Because of short stature and
discrete metaphyseal changes of the wrist (Fig. 1b),
the ACP5 gene encoding tartrate resistant acid phos-
phatase (TRAP) was sequenced. The patient was found
to be compound heterozygous for a missense mutation
(c.131C > T [p.Thr44Met, T44M]) and a frameshift muta-
tion (c.816dupC [p.K272Qfs*14, K272fs]) which was
predicted to result in a truncated protein. The T44M mu-
tation was listed in the ENSEMBL database with an allele
frequency of 0.0001 and was predicted to be pathogen
(SIFT: deleterious; POLYPHEN: probably damaging). Both
parents were found to be heterozygous for one of the
mutations. Biochemically, TRAP activity was undetectable
in the patient, while both parents exhibited markedly
decreased TRAP levels (mother 1.5 U/l [<4.3 U/l]; father
2.2 U/l [<5.4 U/l]) confirming the diagnosis of SPENCD.
The patient was found to exhibit up-regulation of
interferon-stimulated genes in peripheral blood (Fig. 2).
Interestingly, both clinically healthy parents also showed an
interferon signature in peripheral blood (Fig. 2). Antibodies
to nuclear antigens were detected in the mother’s blood.
Discussion
We describe an unusual case of SPENCD due to two
hitherto unknown mutations in the ACP5 gene leading
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Fig. 2 Molecular findings. a Pedigree of patient’s family with ACP5 gene mutations indicated. b Pherograms showing ACP5 gene mutations as
sequenced in the patient. c Expression of IFNB and the interferon-stimulated genes IFI6, IFI44, DDX58 and IFI27 in peripheral blood cells normalized
to GAPDH. Indicated are the fold changes in gene expression relative to the mean gene expression of 2 wild type controls. Gene expression was
determined by quantitative RT-PCR. Shown are the means ± SEM of triplicate measurements. *p < 0.05; **p < 0.01; ***p < 0.001, 2-tailed Student’s t test
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to complete loss of TRAP activity in the patient’s serum.
The clinical picture of the patient reported here is charac-
terized by neurological impairment due to cerebral vascular
disease as well as severe immune dysregulation resulting in
autoimmunity and immunodeficiency. Thus, in addition to
autoimmune haemolytic anaemia, thrombocytopenia, poly-
arthritis, hepatitis and nephritis, the patient presented with
life threatening hyperreactivity to viral infections as well as
recurrent bacterial infections. This is in contrast to the very
mild signs of skeletal dysplasia observed in this patient.
Although short stature has been attributed to non-ossified
lesions affecting the area of the growth plate the long bones
and the spine [2], the growth retardation observed in our
patient cannot be fully explained by the disturbances of
bone growth, but may also be related to chronic consuming
disease as well as nutritional factors.
Osteopontin functions as a major regulator of bone re-
sorption in osteoclasts and stimulator of interferon-alpha
production in plasmacytoid dendritic cells [6, 7]. Dephos-
phorylation of osteopontin by TRAP down regulates
osteopontin activity. Indeed, patients with SPENCD were
shown to exhibit higher levels of active osteopontin in
serum, urine and dendritic cells [5]. Furthermore, TRAP-
deficient dendritic cells secrete Th1-polarizing proinflam-
matory cytokines such as TNF-α [5]. In addition, a consti-
tutive up-regulation of interferon-regulated genes was
demonstrated in patients with SPENCD [4]. Consistent
with chronic activation of the innate immune system, we
demonstrate increased levels of type I interferon in CSF
and serum as well as overexpression of interferon-
stimulated genes in peripheral blood cells of the patient.
Type I interferons have pronounced immunostimulatory
effects and play a central role in antiviral defense. Indeed,
chronic overproduction of type I interferons may have led
to the hyperreactive inflammatory responses caused by
viral infections in the patient. In addition, type I inter-
ferons play a central role in SLE pathogenesis by promot-
ing the release of nuclear antigens from dying cells and
maturation of autoreactive B-cells thereby inducing auto-
immunity [8]. Interestingly, reduced level of TRAP and an
interferon-signature is also observed in the clinically
healthy parents. Of note, heterozygous mutations in
TREX1 and the RNASEH2 genes, which cause the type I
interferonopathy Aicardi-Goutières syndrome, confer an
increased risk for SLE [9, 10] raising the question as to
whether constitutive activation of antiviral immunity in
parents of patients with SPENCD may also increase the
risk for autoimmune disease later in life.
Type I interferonopathies such as Aicardi-Goutières
syndrome and SPENCD constitute an emerging group
of genetically determined diseases that are characterized
by overproduction of antiviral type I interferon [11].
Although clinically distinct and genetically heterogeneous,
these disorders share some phenotypic features such as
neurological impairment including brain calcifications,
multisystem inflammation and autoimmunity. Currently,
there is no specific treatment available for these patients.
However, our knowledge on the underlying pathome-
chanims suggests that patients with SPENCD may
therapeutically benefit from inhibition of type I inter-
feron signalling.
Conclusion
SPENCD is a type I interferonopathy that may present
with absent or very discrete signs of skeletal dysplasia.
SPENCD should be considered in an infant or young
child presenting with recurrent systemic inflammation,
particularly if triggered by viral infections, immunod-
eficiency, autoimmunity and developmental delay even
in the absence of metaphyseal dysplasia. Heterozygous
parents of SPENCD patients exhibit an interferon signa-
ture in blood and may therefore be at increased risk for
autoimmune disease.
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